Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | PTGIR | P43119 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1801451 | 0.80 | ESR1 (0.43) | ESR1ALDH1A1HSD17B10ALOX15NR1I2 | |
| SCHEMBL5201246 | 0.77 | MAPT (0.47) | MEN1KMT2AALDH1A1HSD17B10KDM4E | |
| SCHEMBL15656520 | 0.72 | ALDH1A1 (0.44) | ESR1ALDH1A1RAB9AHSD17B10ALOX15 | |
| SCHEMBL5200953 | 0.72 | HTT (0.42) | KMT2AALDH1A1 | |
| SCHEMBL18740054 | 0.71 | MAPK1 (0.55) | MEN1KMT2AALDH1A1RAB9AHSD17B10 | |
| SCHEMBL11168658 | 0.69 | SMN1; SMN2 (0.47) | ALDH1A1HSD17B10ALOX15PTGIR | |
| SCHEMBL13858547 | 0.69 | CA1 (0.48) | MEN1KMT2AALDH1A1RAB9AHSD17B10 | |
| SCHEMBL1720030 | 0.69 | POLB (0.66) | MEN1KMT2AALDH1A1RAB9AKDM4E | |
| SCHEMBL4708836 | 0.68 | CSF1R (0.70) | MEN1KMT2AALOX15TSHR | |
| SCHEMBL6004377 | 0.67 | KDM4E (0.43) | MEN1KMT2AALDH1A1HSD17B10PTGIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1817379-A2 | PYRAZOLE AZOMETHINES AND COLORANTS CONTAINING THESE COMPOUNDS | The Procter and Gamble Company (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20070033742-A1 | Pyrazole azomethines and colorants containing these compounds | PROCTER & GAMBLE COMPANY, THE | 2007-02-15 | — | — | US | disclosed |
| WO-2006060564-A2 | PYRAZOLE AZOMETHINES AND COLORANTS CONTAINING THESE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2006-06-08 | — | — | WO | disclosed |
| WO-1992004349-A1 | THERAPEUTIC AGENTS | PFIZER LIMITED (GB) | 1992-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070033742-A1 | Pyrazole azomethines and colorants containing these compounds | KRT18, NOX5, TUBB3 | ESR1 3782/4885MEN1 4593/4885KMT2A 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.